{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:07:50Z","timestamp":1793725670915,"version":"4.6.1"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ajo.2025.05.007","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T10:57:47Z","timestamp":1747393067000},"page":"148-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"C","title":["Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries"],"prefix":"10.1016","volume":"277","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4603-826X","authenticated-orcid":false,"given":"Moiz","family":"Lakhani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4013-1112","authenticated-orcid":false,"given":"Angela T.H.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2692-0759","authenticated-orcid":false,"given":"Andrew","family":"Mihalache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-5968","authenticated-orcid":false,"given":"Marko M.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keean","family":"Nanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5014-561X","authenticated-orcid":false,"given":"Jim S.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2999-6782","authenticated-orcid":false,"given":"Alessandro","family":"Feo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-7747","authenticated-orcid":false,"given":"David","family":"Rabinovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reut","family":"Shor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4939-3306","authenticated-orcid":false,"given":"SriniVas","family":"Sadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4018-2702","authenticated-orcid":false,"given":"David","family":"Sarraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6738-7225","authenticated-orcid":false,"given":"Edward A.","family":"Margolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0348-5096","authenticated-orcid":false,"given":"Peter J.","family":"Kertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9988-4146","authenticated-orcid":false,"given":"Varun","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0465-6472","authenticated-orcid":false,"given":"Rajeev H.","family":"Muni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ajo.2025.05.007_bib0001","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ajo.2025.05.007_bib0002","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ajo.2025.05.007_bib0003","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajo.2025.05.007_bib0004","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ajo.2025.05.007_bib0005","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early Parkinson\u2019s disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ajo.2025.05.007_bib0006","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2025.05.007_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ajo.2025.05.007_bib0008","article-title":"GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.ajo.2025.05.007_bib0009","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.numecd.2021.10.003","article-title":"The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system","volume":"32","author":"Yang","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"8","key":"10.1016\/j.ajo.2025.05.007_bib0010","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.05.007_bib0011","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/ejhpharm-2024-004333","article-title":"Potential risk of non-arteritic anterior ischaemic optic neuropathy in semaglutide users: pharmacovigilance insights","volume":"32","author":"Castellana","year":"2025","journal-title":"Eur J Hosp Pharm"},{"issue":"3","key":"10.1016\/j.ajo.2025.05.007_bib0012","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/14740338.2024.2419989","article-title":"Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology","volume":"24","author":"Luo","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ajo.2025.05.007_bib0013","doi-asserted-by":"crossref","DOI":"10.1007\/s12020-024-04112-8","article-title":"Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database","author":"Zhou","year":"2024","journal-title":"Endocrine"},{"issue":"19","key":"10.1016\/j.ajo.2025.05.007_bib0014","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajo.2025.05.007_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2017-000475","article-title":"Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA adverse event reporting system","volume":"6","author":"Fadini","year":"2018","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"10","key":"10.1016\/j.ajo.2025.05.007_bib0016","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00592-017-1031-9","article-title":"Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"54","author":"Dicembrini","year":"2017","journal-title":"Acta Diabetol"},{"issue":"1","key":"10.1016\/j.ajo.2025.05.007_bib0017","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/dom.13484","article-title":"Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: a systematic review and meta-analysis","volume":"21","author":"Avgerinos","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.ajo.2025.05.007_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100547","article-title":"The effect of glucagon-like peptide-1 receptor agonists on diabetic retinopathy at a tertiary care center","volume":"4","author":"Joo","year":"2024","journal-title":"Ophthalmol Sci"},{"issue":"100168","key":"10.1016\/j.ajo.2025.05.007_bib0019","article-title":"Long-term use of semaglutide and risk of diabetic retinopathy progression","volume":"15","author":"Stevens","year":"2024","journal-title":"Endocr Metab Sci"},{"issue":"1","key":"10.1016\/j.ajo.2025.05.007_bib0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40261-021-01110-w","article-title":"Semaglutide and diabetic retinopathy risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"42","author":"Wang","year":"2022","journal-title":"Clin Drug Investig"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2025.05.007_bib0021","first-page":"S14","article-title":"Classification and diagnosis of diabetes: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.ajo.2025.05.007_bib0022","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1007\/s40618-024-02441-z","article-title":"The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"47","author":"Caruso","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ajo.2025.05.007_bib0023","article-title":"Association between semaglutide and non-arteritic anterior ischemic optic neuropathy: a multinational population-based real-world study","author":"Chou","year":"2024","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2025.05.007_bib0024","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1177\/19322968241268050","article-title":"Real-world evidence assessment of the risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"18","author":"Klonoff","year":"2024","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.ajo.2025.05.007_bib0025","unstructured":"American Academy of Ophthalmology and North American Neuro-Ophthalmology Society issue advice on weight loss drug and eye health. American Academy of Ophthalmology. 2024. Accessed November 2, 2024. https:\/\/www.aao.org\/newsroom\/news-releases\/detail\/weight-loss-drug-and-eye-health."},{"key":"10.1016\/j.ajo.2025.05.007_bib0026","unstructured":"U.S. Food and Drug Administration. Qlik Sense. Accessed November 10, 2024. https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee\/sheet\/7a47a261-d58b-4203-a8aa-6d3021737452\/state\/analysis."},{"key":"10.1016\/j.ajo.2025.05.007_bib0027","unstructured":"Uppsala Monitoring Centre. About VigiBase. Accessed November 8, 2024. https:\/\/who-umc.org\/vigibase\/."},{"key":"10.1016\/j.ajo.2025.05.007_bib0028","unstructured":"Uppsala Monitoring Centre. Members of the WHO Programme for International Drug Monitoring. Accessed November 26, 2024. https:\/\/who-umc.org\/about-the-who-programme-for-international-drug-monitoring\/member-countries\/."},{"key":"10.1016\/j.ajo.2025.05.007_bib0029","article-title":"Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"issue":"102684","key":"10.1016\/j.ajo.2025.05.007_bib0030","article-title":"Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase","volume":"73","author":"Shen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ajo.2025.05.007_bib0031","article-title":"Cardiovascular and cerebrovascular adverse events associated with intravitreal anti-VEGF monoclonal antibodies: a World Health Organization pharmacovigilance study","author":"Yang","year":"2025132162","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2025.05.007_bib0032","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nbt.2113","article-title":"OpenVigil\u2013free eyeballs on AERS pharmacovigilance data","volume":"30","author":"B\u00f6hm","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"6","key":"10.1016\/j.ajo.2025.05.007_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA - inspection of U.s. american adverse drug events pharmacovigilance data and novel clinical applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ajo.2025.05.007_bib0034","unstructured":"OpenVigil - open tools for data-mining and analysis of pharmacovigilance data. Accessed December 14, 2024. https:\/\/openvigil.sourceforge.net\/."},{"key":"10.1016\/j.ajo.2025.05.007_bib0035","unstructured":"FDA Adverse Event Reporting System (FAERS) Public Dashboard. U.S. Food and Drug Administration. 2023. Accessed December 14, 2024. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard."},{"issue":"4","key":"10.1016\/j.ajo.2025.05.007_bib0036","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-081990","article-title":"Navigating duplication in pharmacovigilance databases: a scoping review","volume":"14","author":"Kiguba","year":"2024","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.ajo.2025.05.007_bib0037","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1038\/s41598-023-27687-0","article-title":"Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA Adverse Event Reporting System Database","volume":"13","author":"Li","year":"2023","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ajo.2025.05.007_bib0038","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40264-022-01162-7","article-title":"Automated drug coding using artificial intelligence: an evaluation of WHODrug Koda on adverse event reports","volume":"45","author":"Meldau","year":"2022","journal-title":"Drug Saf"},{"key":"10.1016\/j.ajo.2025.05.007_bib0039","unstructured":"U.S. Food and Drug Administration. FDA Drug Adverse Events Reporting System FAERS 2021.Accessed March 20, 2025. https:\/\/aws.amazon.com\/marketplace\/pp\/prodview-dtj4qudubgmca#overview."},{"key":"10.1016\/j.ajo.2025.05.007_bib0040","unstructured":"U.S. Food and Drug Administration. Providing regulatory submissions in electronic format: investigational new drug application safety reports; guidance for industry; availability. Federal Register. Accessed April 21, 2025. https:\/\/www.federalregister.gov\/documents\/2024\/04\/01\/2024-06736\/providing-regulatory-submissions-in-electronic-format-investigational-new-drug-application-safety."},{"key":"10.1016\/j.ajo.2025.05.007_bib0041","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.2147\/PPA.S495254","article-title":"Pharmacovigilance in action: Utilizing VigiBase data to improve clozapine safety","volume":"18","author":"De Las Cuevas","year":"2024","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.ajo.2025.05.007_bib0042","unstructured":"OpenVigil - open tools for data-mining and analysis of pharmacovigilance data. Accessed March 19, 2025. https:\/\/openvigil.sourceforge.net\/."},{"key":"10.1016\/j.ajo.2025.05.007_bib0043","unstructured":"MedDRA. Accessed March 19, 2025. https:\/\/www.meddra.org\/about-meddra\/history."},{"issue":"10","key":"10.1016\/j.ajo.2025.05.007_bib0044","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2165\/00002018-200831100-00001","article-title":"An automated standardized system for managing adverse events in clinical research networks","volume":"31","author":"Richesson","year":"2008","journal-title":"Drug Saf"},{"key":"10.1016\/j.ajo.2025.05.007_bib0045","article-title":"A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib","volume":"14","author":"Wu","year":"2023","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.ajo.2025.05.007_bib0046","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1210\/clinem\/dgaa321","article-title":"Cardiovascular benefit of empagliflozin across the spectrum of cardiovascular risk factor control in the EMPA-REG OUTCOME trial","volume":"105","author":"Inzucchi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"10.1016\/j.ajo.2025.05.007_bib0047","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2025.05.007_bib0048","unstructured":"Latif W, Lambrinos KJ, Patel P, Rodriguez R. Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs). StatPearls Publishing; 2024."},{"issue":"4","key":"10.1016\/j.ajo.2025.05.007_bib0049","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/dom.12596","article-title":"Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists","volume":"18","author":"Madsbad","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"101102","key":"10.1016\/j.ajo.2025.05.007_bib0050","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"issue":"6","key":"10.1016\/j.ajo.2025.05.007_bib0051","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/pds.964","article-title":"Comparison of data mining methodologies using Japanese spontaneous reports","volume":"13","author":"Kubota","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1016\/j.ajo.2025.05.007_bib0052","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"issue":"11","key":"10.1016\/j.ajo.2025.05.007_bib0053","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1111\/bcp.14868","article-title":"Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections","volume":"87","author":"B\u00f6hm","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ajo.2025.05.007_bib0054","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"14","key":"10.1016\/j.ajo.2025.05.007_bib0055","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"issue":"9131","key":"10.1016\/j.ajo.2025.05.007_bib0056","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2025.05.007_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson's disease: an in-depth review","volume":"16","author":"Reich","year":"2022","journal-title":"Front Neurosci"},{"issue":"1","key":"10.1016\/j.ajo.2025.05.007_bib0058","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers","volume":"8","author":"N\u00f8rgaard","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"10.1016\/j.ajo.2025.05.007_bib0059","doi-asserted-by":"crossref","first-page":"221","DOI":"10.37349\/eds.2023.00015","article-title":"The protective role of GLP-1 in neuro-ophthalmology","volume":"1","author":"Sheth","year":"2023","journal-title":"Explor Drug Sci"},{"key":"10.1016\/j.ajo.2025.05.007_bib0060","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ajo.2025.05.007_bib0061","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1111\/dom.13339","article-title":"Glucagon-like peptide-1 receptor expression in the human eye","volume":"20","author":"Hebsgaard","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.ajo.2025.05.007_bib0062","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0002-9394(14)73082-X","article-title":"Salvage of vision after hypotension-induced ischemic optic neuropathy","volume":"117","author":"Connolly","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.05.007_bib0063","doi-asserted-by":"crossref","DOI":"10.2174\/0118761429273223231124072223","article-title":"Molecular insight into the apoptotic mechanism of cancer cells: an explicative review","volume":"17","author":"Karati","year":"2024","journal-title":"Curr Mol Pharmacol"},{"issue":"16","key":"10.1016\/j.ajo.2025.05.007_bib0064","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1089\/ars.2019.8008","article-title":"Hypoglycemia induces mitochondrial reactive oxygen species production through increased fatty acid oxidation and promotes retinal vascular permeability in diabetic mice","volume":"34","author":"Yoshinaga","year":"2021","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.ajo.2025.05.007_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/7489795","article-title":"Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications. Sardu C, ed","volume":"2020","author":"Papachristoforou","year":"2020","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.ajo.2025.05.007_bib0066","doi-asserted-by":"crossref","DOI":"10.2174\/0118761429308361240823061634","article-title":"Recent advances in the glycolytic processes linked to tumor metastasis","volume":"17","author":"Qiong","year":"2024","journal-title":"Curr Mol Pharmacol"},{"issue":"7","key":"10.1016\/j.ajo.2025.05.007_bib0067","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/09553002.2019.1589653","article-title":"The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression","volume":"95","author":"Vaupel","year":"2019","journal-title":"Int J Radiat Biol"},{"issue":"12","key":"10.1016\/j.ajo.2025.05.007_bib0068","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0186-y","article-title":"Differential effects of type 1 diabetes mellitus and subsequent osteoblastic \u03b2-catenin activation on trabecular and cortical bone in a mouse model","volume":"50","author":"Chen","year":"2018","journal-title":"Exp Mol Med"},{"issue":"10","key":"10.1016\/j.ajo.2025.05.007_bib0069","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00125-008-1084-y","article-title":"The WNT signalling pathway and diabetes mellitus","volume":"51","author":"Jin","year":"2008","journal-title":"Diabetologia"},{"issue":"28","key":"10.1016\/j.ajo.2025.05.007_bib0070","doi-asserted-by":"crossref","first-page":"11402","DOI":"10.1073\/pnas.1205015109","article-title":"Chemical and genetic evidence for the involvement of Wnt antagonist Dickkopf2 in regulation of glucose metabolism","volume":"109","author":"Li","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"10.1016\/j.ajo.2025.05.007_bib0071","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1073\/pnas.0701509104","article-title":"Wnt signaling regulates pancreatic beta cell proliferation","volume":"104","author":"Rulifson","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajo.2025.05.007_bib0072","doi-asserted-by":"crossref","DOI":"10.2174\/0118761429266116231123160809","article-title":"The regulatory mechanism of hypoxia-inducible factor 1 and its clinical significance","volume":"17","author":"Yin","year":"2024","journal-title":"Curr Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.ajo.2025.05.007_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111976","article-title":"HIF-1\u03b1 accumulation in response to transient hypoglycemia may worsen diabetic eye disease","volume":"42","author":"Guo","year":"2023","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.ajo.2025.05.007_bib0074","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/dom.13538","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.ajo.2025.05.007_bib0075","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/jamaophthalmol.2022.5817","article-title":"Outcomes and complications of pars Plana vitrectomy for tractional retinal detachment in people with diabetes: a systematic review and meta-analysis: a systematic review and meta-analysis","volume":"141","author":"McCullough","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2025.05.007_bib0076","unstructured":"Update on Semaglutide Risks. American Academy of Ophthalmology. 2021. Accessed November 24, 2024. https:\/\/www.aao.org\/eyenet\/article\/update-on-semaglutide-risks."},{"issue":"1","key":"10.1016\/j.ajo.2025.05.007_bib0077","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41433-021-01741-5","article-title":"Semaglutide and the risk of diabetic retinopathy-current perspective","volume":"36","author":"Sharma","year":"2022","journal-title":"EYE"},{"issue":"1","key":"10.1016\/j.ajo.2025.05.007_bib0078","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diacare.10.1.1","article-title":"DCCT): results of feasibility study. The DCCT Research Group","volume":"10","year":"1987","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ajo.2025.05.007_bib0079","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2125.1999.00092.x","article-title":"The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes: Therapeutic implications of the UKPDS","volume":"48","author":"King","year":"1999","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.ajo.2025.05.007_bib0080","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/archopht.116.7.874","article-title":"Early worsening of diabetic retinopathy in the diabetes control and complications trial","volume":"116","year":"1998","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.05.007_bib0081","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-017-0213-3","article-title":"Mechanism of worsening diabetic retinopathy with rapid lowering of blood glucose: the synergistic hypothesis","volume":"17","author":"Jingi","year":"2017","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"10.1016\/j.ajo.2025.05.007_bib0082","doi-asserted-by":"crossref","first-page":"424","DOI":"10.4239\/wjd.v14.i4.424","article-title":"Semaglutide-eye-catching results","volume":"14","author":"Cigrovski","year":"2023","journal-title":"World J Diabetes"},{"issue":"4","key":"10.1016\/j.ajo.2025.05.007_bib0083","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ajo.2025.05.007_bib0084","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab"},{"issue":"2","key":"10.1016\/j.ajo.2025.05.007_bib0085","doi-asserted-by":"crossref","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with Type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes care"},{"issue":"1","key":"10.1016\/j.ajo.2025.05.007_bib0086","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.japh.2023.10.037","article-title":"The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception","volume":"64","author":"Skelley","year":"2024","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"17","key":"10.1016\/j.ajo.2025.05.007_bib0087","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ajo.2025.05.007_bib0088","article-title":"Characterization and corroboration of safety signals identified from the US food and drug administration adverse event reporting system, 2008-19: cross sectional study","volume":"379","author":"Dhodapkar","year":"2022","journal-title":"BMJ"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425002399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425002399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T13:18:52Z","timestamp":1754918332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425002399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":88,"alternative-id":["S0002939425002399"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.05.007","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}